● Not Yet Recruiting

A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis

Condition: Chronic Obstructive Pulmonary Disease With Chronic Bronchitis · Sponsor: UCB Biopharma SRL

PhasePhase 2

Planned participants402

Who can joinAll sexes, 40 Years to 80 Years

Healthy volunteersNo

About this study

The purpose of the study is to investigate the efficacy of galvokimig versus placebo in the time to the first acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in study participants with moderate-to-severe COPD with chronic bronchitis.

This description comes directly from the study's public registry record.

Talk to the study team

UCB Cares · 1-844-599-2273 (USA) · ucbcares@ucb.com

UCB Care · 0018445992273 · ucbcares@ucb.com

Always discuss trial participation with your own doctor first.

Locations (0)

Locations not yet listed on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07725939